How to Address E-cigarette Usage Among the Canadian Adolescent Population
McMaster University Journal of Public Health · 10.11.2024 · 2
DOI: 10.15173/mujph.v2i1.3770 ↗Kurz gefasst
Fachartikel in der Zeitschrift McMaster University Journal of Public Health, online erschienen am 10.11.2024. Verfasst von Djaka Cherif und 1 weiteren Autor:innen.
Abstract (Originalsprache)
This opinion article provides a comprehensive analysis of electronic cigarette (e-cigarette) use, focusing on decision-making determinants, socio-environmental influences, policy implications, marketing strategies, and access patterns. Tracing the historical trajectory of e-cigarettes from their inception to contemporary usage, the review elucidates factors shaping adolescents' vaping decisions, gender disparities, and the impact of social media platforms. Comparative analysis of global policies underscores diverse regulatory approaches, ranging from stringent bans in Australia to the UK's endorsement of e-cigarettes for smoking cessation. An in-depth examination of marketing tactics and access channels underscores their implications for public health. Despite inherent limitations such as sampling biases and regulatory disparities, the review underscores the imperative for evidence-based interventions to address emerging public health challenges associated with e-cigarette use among Canadian adolescents.
Zitieren
APA
Cherif, D., & Kalo, C. (2024). How to Address E-cigarette Usage Among the Canadian Adolescent Population. McMaster University Journal of Public Health, 2. https://doi.org/10.15173/mujph.v2i1.3770
Vancouver
Cherif D, Kalo C. How to Address E-cigarette Usage Among the Canadian Adolescent Population. McMaster University Journal of Public Health. 2024;2. doi:10.15173/mujph.v2i1.3770
BibTeX
@article{Cherif2024,
author = {Cherif, Djaka and Kalo, Carmen},
title = {How to Address E-cigarette Usage Among the Canadian Adolescent Population},
journal = {McMaster University Journal of Public Health},
year = {2024},
volume = {2},
doi = {10.15173/mujph.v2i1.3770}
}
EUVIMED